January 2024

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis –  Primary efficacy endpoints: NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD

NEW YORK, Jan. 22, 2024 /PRNewswire/ — The train battery market is expected to grow by USD 179.11 million from 2022 to 2027, according to Technavio. In addition, the growth momentum will progress at a CAGR of 5.45% during the forecast period. The report analyzes the competitive landscape

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: